IMNM
Price
$10.52
Change
+$0.72 (+7.35%)
Updated
Sep 5 closing price
Capitalization
915.71M
71 days until earnings call
PDSB
Price
$1.20
Change
-$0.02 (-1.64%)
Updated
Sep 5 closing price
Capitalization
56.43M
66 days until earnings call
Interact to see
Advertisement

IMNM vs PDSB

Header iconIMNM vs PDSB Comparison
Open Charts IMNM vs PDSBBanner chart's image
Immunome
Price$10.52
Change+$0.72 (+7.35%)
Volume$1.36M
Capitalization915.71M
PDS Biotechnology
Price$1.20
Change-$0.02 (-1.64%)
Volume$304.12K
Capitalization56.43M
IMNM vs PDSB Comparison Chart in %
Loading...
IMNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMNM vs. PDSB commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a StrongBuy and PDSB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (IMNM: $10.52 vs. PDSB: $1.20)
Brand notoriety: IMNM and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNM: 170% vs. PDSB: 61%
Market capitalization -- IMNM: $915.71M vs. PDSB: $56.43M
IMNM [@Biotechnology] is valued at $915.71M. PDSB’s [@Biotechnology] market capitalization is $56.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNM’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • IMNM’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMNM and PDSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNM’s TA Score shows that 7 TA indicator(s) are bullish while PDSB’s TA Score has 6 bullish TA indicator(s).

  • IMNM’s TA Score: 7 bullish, 2 bearish.
  • PDSB’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, IMNM is a better buy in the short-term than PDSB.

Price Growth

IMNM (@Biotechnology) experienced а +10.62% price change this week, while PDSB (@Biotechnology) price change was -3.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

IMNM is expected to report earnings on Nov 17, 2025.

PDSB is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMNM($916M) has a higher market cap than PDSB($56.4M). IMNM YTD gains are higher at: -0.942 vs. PDSB (-26.380). PDSB has higher annual earnings (EBITDA): -32.36M vs. IMNM (-187.92M). IMNM has more cash in the bank: 268M vs. PDSB (31.9M). IMNM has less debt than PDSB: IMNM (4.14M) vs PDSB (18.5M). IMNM has higher revenues than PDSB: IMNM (12.6M) vs PDSB (0).
IMNMPDSBIMNM / PDSB
Capitalization916M56.4M1,624%
EBITDA-187.92M-32.36M581%
Gain YTD-0.942-26.3804%
P/E RatioN/AN/A-
Revenue12.6M0-
Total Cash268M31.9M840%
Total Debt4.14M18.5M22%
FUNDAMENTALS RATINGS
PDSB: Fundamental Ratings
PDSB
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IMNMPDSB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 16 days ago
82%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
IMNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACDSF2.150.01
+0.47%
Ascendas Real Estate Investment Trust
DWIS0.11N/A
N/A
Dinewise, Inc.
ORPEF14.22N/A
N/A
Orpea ACT
BAMGF14.65N/A
N/A
BROOKFIELD CORP.
HONT125.00N/A
N/A
Honat Bancorp, Inc.

IMNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with IDYA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMNM
1D Price
Change %
IMNM100%
+7.35%
IDYA - IMNM
59%
Loosely correlated
+5.15%
DNTH - IMNM
55%
Loosely correlated
+7.46%
SYRE - IMNM
54%
Loosely correlated
+0.06%
RXRX - IMNM
53%
Loosely correlated
+1.99%
IPSC - IMNM
53%
Loosely correlated
+5.41%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with DYN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-1.64%
DYN - PDSB
44%
Loosely correlated
+7.40%
IDYA - PDSB
44%
Loosely correlated
+5.15%
ARCT - PDSB
43%
Loosely correlated
+6.50%
RXRX - PDSB
42%
Loosely correlated
+1.99%
IMNM - PDSB
42%
Loosely correlated
+7.35%
More